{
    "2019-07-26": [
        [
            {
                "time": "2018-07-26",
                "original_text": "格隆汇港股聚焦(7.26)︱融创中国料上半年净利同比增逾45% 中信建投上半年净利升37.61%至23.3亿元",
                "features": {
                    "keywords": [
                        "融创中国",
                        "净利增长",
                        "中信建投",
                        "上半年业绩"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "房地产",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-26",
                "original_text": "复星医药：子公司获临床试验通知书",
                "features": {
                    "keywords": [
                        "复星医药",
                        "临床试验",
                        "子公司"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-26",
                "original_text": "复星医药控股子公司收到国家药品监督管理局签发的《临床试验通知书》",
                "features": {
                    "keywords": [
                        "复星医药",
                        "临床试验",
                        "国家药品监督管理局"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-26",
                "original_text": "复星医药(600196.SH)：重组人促红素-HyFc融合蛋白注射液用于治疗肾性贫血获准开展临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "重组人促红素",
                        "肾性贫血",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-26",
                "original_text": "复星医药(02196.HK)子公司治疗肾性贫血新药获准开展临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "肾性贫血",
                        "新药",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-26",
                "original_text": "同仁堂科技跌近4% 被中金降级至中性评级 投资评级恶化",
                "features": {
                    "keywords": [
                        "同仁堂科技",
                        "投资评级",
                        "中金公司",
                        "降级"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}